全球大型製藥企業的聯盟條件與契約 (2020～2024年)

本報告提供了有關公司為何以及在什麼條件下與主要製藥公司進行合作的詳細資訊和分析。這些協議往往是多方面的，從聯合研發開始，一直到成果的商業化。

本報告提供了自 2020 年以來生命科學領域宣布的 2,022 項主要製藥公司協議的詳細資訊。

本報告全面回顧了主要製藥公司之間的合約趨勢、主要公司、主要合約金額和合約財務，並研究了各公司如何、為何以及在什麼條件下與主要製藥公司簽訂了合作協議，您可以了解什麼。

本報告從財務角度評估主要製藥公司的交易期限和價值，並提供交易總額、預付款、里程碑和特許權使用費等信息，幫助讀者了解交易的財務價值。

本報告的中間部分研究了大型製藥公司的合作夥伴和主要交易者。報告了大型製藥公司中關鍵交易的交易價值和最活躍的交易撮合者，讓讀者了解哪些公司在這個充滿活力的交易市場中取得了成功。

交易各方揭露的主要藥企網上交易記錄，包含在以下目錄格式：

• 公司名稱（A-Z）
• 發展階段
• 交易類型
• 治療重點領域
• 技術類型
• 此外，我們也會記錄公司及其關聯公司向美國證券交易委員會提交的合約文件（如果有）。雖然許多公司希望了解其付款條件的詳細信息，但在付款方式方面，細節才是王道。
• 本報告也包含一些圖表，顯示 2020 年以來大型製藥公司的聯盟和交易趨勢和活動。
• 總而言之，本報告提供了潛在交易者需要了解的有關主要製藥公司研發和商業化合作夥伴關係的所有資訊。

主要優點

該報告為讀者提供了以下主要好處：

• 主要製藥公司合約趨勢的詳細資料（2020年起）
• 取得交易金額、預付款、里程碑和版稅率數據
• 主要製藥公司與主要生物製藥公司簽署的實際協議：查看詳細信息
• 確定大型製藥公司最活躍的交易撮合者（2020 年及以後）
• 公司過去同意的主要合約條件的說明
• 進行盡職調查：評估向合作夥伴公司提出的合約條款的適當性

調查範圍

• 本報告旨在讓讀者深入了解和了解全球領先公司與大型製藥公司達成的交易的趨勢和結構。

主要製藥公司的合作條件和合約細節：

• 生醫產業主要藥廠交易趨勢（2020年後）
• 取得交易金額、預付款、里程碑和版稅率數據
• 取得主要製藥公司的合約文件
• 與主要製藥公司的交易金額（2020年起）
• 大型製藥公司中最活躍的交易撮合者（2020 年起）

此報告列出了可用合約的以下資訊：

• 公司名稱（A-Z）
• 總交易金額
• 合約簽訂時的開發階段
• 合約組成部分的類型
• 具體治療標靶
• 技術類型
• 每筆交易的標題都透過網路連結連結到交易記錄的線上版本以及合約文件（如果有），從而可以輕鬆按需存取每份合約文件。
• 此報告提供對大型製藥公司可用交易和合約文件的全面存取。

透過分析實際合同，可以評估：

• 授予或選擇的具體權利是什麼？
• 合約實際上賦予了合作夥伴公司什麼？
• 授予哪些類型的專有權？
• 合約的付款結構是怎樣的？
• 如何審核銷售和付款？
• 合約期限是多久？
• 合約的主要條款是如何定義的？
• 智慧財產權的處理和所有權如何？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和發布？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已就何種類型的分授權或分包條款達成協議？
• 公司主張哪些樣板條款？
• 根據合作夥伴關係或交易的類型，哪些樣板條款看起來有所不同？
• 公司對契約法主張哪一個管轄權？

目錄

執行摘要

第一章簡介

第二章主要藥企交易走勢

• 簡介
• 主要製藥公司之間的長期聯盟趨勢
• 主要製藥公司最活躍的交易撮合者
• 主要製藥公司之間的合作趨勢：按交易類型劃分
• 主要製藥公司之間的聯盟趨勢：按治療領域
• 主要製藥公司之間的合作趨勢：依技術類型劃分
• 與各大藥廠合作的條件
  • 與主要製藥公司聯盟的交易總額
  • 主要製藥公司交易的預付款
  • 主要製藥公司交易的里程碑付款
  • 主要藥廠的專利費率

第三章主要醫藥企業重大交易

• 簡介
• 主要製藥公司的主要交易：交易金額

第 4 章主要藥廠最活躍的交易撮合者

• 簡介
• 大藥廠最活躍的交易撮合者
• 大藥廠最活躍的合作夥伴：簡介

第五章主要藥廠合約交易一覽

• 簡介
• 主要藥廠合約交易列表

第六章主要製藥公司交易趨勢：依技術類型劃分

附錄

Global Big Pharma Partnering Terms and Agreements 2020 to 2024 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of 2,022 Big Pharma agreements announced in the life sciences since 2020.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Online deal records of Big Pharma deals as disclosed by the deal parties are included in a directory format by:

• Company A-Z
• Stage of development
• Deal type
• Therapy focus
• Technology type
• In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
• The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2020, including details of headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Big Pharma deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.
• Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2020, where a contract document is available in the public domain. Each deal title links via hyperlink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2020. The chapter is organized by specific technology type. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
• A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
• The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2020.
• In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

Global Big Pharma Partnering Terms and Agreements 2020-2024 provides the reader with the following key benefits:

• In-depth understanding of Big Pharma deal trends since 2020
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
• Identify most active Big Pharma dealmakers since 2020
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Big Pharma Partnering Terms and Agreements 2020-2024 is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

Big Pharma Partnering Terms and Agreements includes:

• Trends in Big Pharma dealmaking in the biopharma industry since 2020
• Access to headline, upfront, milestone and royalty data
• Access to Big Pharma contract documents
• Leading Big Pharma deals by value since 2020
• Most active Big Pharma dealmakers since 2020

In Global Big Pharma Partnering Terms and Agreements 2020-2024, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• The Global Big Pharma Partnering Terms and Agreements 2020-2024 report provides comprehensive access to available Big Pharma deals and contract documents.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

• 2.1. Introduction
• 2.2. Big Pharma partnering over the years
• 2.3. Most active Big Pharma dealmakers
• 2.4. Big Pharma partnering by deal type
• 2.5. Big Pharma partnering by therapy area
• 2.6. Big Pharma partnering by technology type
• 2.7. Deal terms for Big Pharma partnering
  • 2.7.1 Big Pharma partnering headline values
  • 2.7.2 Big Pharma deal upfront payments
  • 2.7.3 Big Pharma deal milestone payments
  • 2.7.4 Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

• 3.1. Introduction
• 3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

• 4.1. Introduction
• 4.2. Most active Big Pharma dealmakers
• 4.3. Most active Big Pharma partnering company profiles

Chapter 5 - Big Pharma contracts dealmaking directory

• 5.1. Introduction
• 5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Appendices

• Appendix 1 - Big Pharma deals by company A-Z
• Appendix 2 - Big Pharma deals by stage of development
• Appendix 3 - Big Pharma deals by deal type
• Appendix 4 - Big Pharma deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Big Pharma partnering since 2020
• Figure 2: Active Big Pharma dealmaking activity 2020-2024
• Figure 3: Big Pharma partnering by deal type since 2020
• Figure 4: Big Pharma partnering by disease type since 2020
• Figure 5: Big Pharma partnering by technology type since 2020
• Figure 6: Big Pharma deals with a headline value
• Figure 7: Big Pharma deals with an upfront value
• Figure 8: Big Pharma deals with a milestone value
• Figure 9: Big Pharma deals with a royalty rate value
• Figure 10: Top Big Pharma deals by value since 2020
• Figure 11: Most active Big Pharma dealmakers 2020-2024